Update to Faron's Financial Calendar and Date of the Annual General Meeting in 2026

TURKU, FINLAND / ACCESS Newswire / March 9, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces an update for the Company's financial calendar 2026.

The Annual General Meeting is now planned to take place on 4 May 2026, instead of 30 March 2026 as previously communicated. Faron's Board of Directors will issue a separate company announcement in due course to formally convene the meeting.

The publication date of Faron's half-year financial report for the period January 1 to June 30, 2026, remains unchanged being Wednesday 26 August 2026.

For more information, please contact:

About bexmarilimab
Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The company's lead asset, bexmarilimab, is a novel macrophage-guiding immunotherapy being investigated in multiple oncology settings. Further information is available at www.faron.com.

SOURCE: Faron Pharmaceuticals Ltd.